All In Biotech

Drug Trial Radar · NCT03930732

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 939 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

939

Actual

Start

Apr 15, 2019

Primary completion

Feb 8, 2023

Study completion May 2, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate and severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Dupilumab SAR231893Drug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

  • Inhaled CorticosteroidDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • Inhaled Long-Acting Beta AgonistDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • Inhaled Long-Acting Muscarinic AntagonistDrug

    Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation

  • PlaceboDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment PeriodTime frame: Baseline (Day 1) to Week 52

Locations

275 sites in 24 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research, LLC-Site Number:8400030

    Andalusia, Alabama

  • Clinical Research Center of Alabama, LLC-Site Number:8400041

    Birmingham, Alabama

  • UAB Lung Health Center-Site Number:8400013

    Birmingham, Alabama

  • SEC Clinical Research, LLC-Site Number:8400059

    Dothan, Alabama

  • Pulmonary Associates of Mobile, P.C.-Site Number:8400057

    Mobile, Alabama

  • Asthma and Allergy Associates, PC-Site Number:8400034

    Colorado Springs, Colorado

  • Clinical Research Of West Florida Inc-Site Number:8400010

    Clearwater, Florida

  • Finlay Medical Research-Site Number:8400014

    Greenacres City, Florida

  • Project 4 research, Inc.-Site Number:8400023

    Miami, Florida

  • Finlay Medical Research-Site Number:8400062

    Miami, Florida

  • Renstar Medical Research-Site Number:8400051

    Ocala, Florida

  • Florida Institute for Clinical Research, LLC-Site Number:8400029

    Orlando, Florida

  • Emerald Coast Research Associates-Site Number:8400032

    Panama City, Florida

  • Sarasota Clinical Research-Site Number:8400026

    Sarasota, Florida

  • VitaLink research-Hamilton Mill-Site Number:8400055

    Dacula, Georgia

  • DC Research Works-Site Number:8400016

    Marietta, Georgia

  • North Georgia Clinical Research-Site Number:8400025

    Woodstock, Georgia

  • Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400012

    Baltimore, Maryland

  • Asthma Allergy & Sinus Center-Site Number:8400038

    White Marsh, Maryland

  • Michigan Medicine (University of Michigan)-Site Number:8400050

    Ann Arbor, Michigan

  • Mayo Clinic Lanmark Center 2-46-Site Number:8400065

    Rochester, Minnesota

  • Midwest Chest Consultants, P.C.-Site Number:8400011

    Saint Charles, Missouri

  • Washington University School of Medicine-Site Number:8400004

    St Louis, Missouri

  • Sierra Clinical Research-Site Number:8400035

    Las Vegas, Nevada

  • Va Western New York Healthcare-Site Number:8400067

    Buffalo, New York

  • IMA Clinical Research, LLC-Site Number:8400070

    New York, New York

  • The University of North Carolina at Chapel Hill - Division of Pulmonary and Critical Care Medicine-Site Number:8400019

    Chapel Hill, North Carolina

  • American Health Research-Site Number:8400061

    Charlotte, North Carolina

  • Duke Asthma, Allergy and Airway Center-Site Number:8400064

    Durham, North Carolina

  • Accellacare-Site Number:8400052

    Wilmington, North Carolina

  • Southeastern Research Center-Site Number:8400060

    Winston-Salem, North Carolina

  • Midwest Pulmonary and Sleep Research Center-Site Number:8400040

    Dayton, Ohio

  • Aventiv Research, Inc-Site Number:8400024

    Dublin, Ohio

  • OK Clinical Research-Site Number:8400005

    Edmond, Oklahoma

  • Velocity Clinical Research, Medford-Site Number:8400001

    Medford, Oregon

  • Jefferson Associates in Internal Medicine-Site Number:8400037

    Clairton, Pennsylvania

  • Temple University Hospital-Site Number:8400009

    Philadelphia, Pennsylvania

  • Emphysema COPD Research Center, Kaufmann Medical Building-Site Number:8400033

    Pittsburgh, Pennsylvania

  • Berks Schuylkill Respiratory Specialists, LTD-Site Number:8400063

    Wyomissing, Pennsylvania

  • VitaLink Research-Easley-Site Number:8400022

    Easley, South Carolina

Showing 40 of 275 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.